Arkolith/Insider Trading/TRVI/Form 4

Sciascia Thomas

Chief Scientific OfficerTrevi Therapeutics, Inc. (TRVI) · full profile →Form 4 · filed Aug 21, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$49K
Net Open-Market Flow
-$49K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 19, 2024Option exercise(M)16K$1.43$24K237K
Aug 19, 2024Sell(S)16K$2.96$49K220K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 19, 2024Option exercise(M)16K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-099481) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML